厄贝沙坦氢氯噻嗪片对原发性高血压患者血压及血压变异性的影响

目的 观察厄贝沙坦氢氯噻嗪片对原发性高血压病患者血压及血压变异性(BPV)的影响.方法 60例2级原发性高血压患者服用厄贝沙坦氢氯噻嗪片150 mg/d,动态监测治疗前与治疗8周后24h血压,分析比较治疗前后血压及BPV的变化.结果 治疗过程中,3例患者因1周后血压未达标而加服苯磺酸氨氯地平片,退出本研究,有效例数57例.①治疗后与治疗前相比,24 h SBP均值、白昼SBP均值、白昼DBP均值及夜间SBP均值差异有统计学意义[(122 ±8)mm Hg(1 mm Hg=0.133 kPa)比(151 ±24) mm Hg,(127±18) mm Hg比(156±19)mm Hg,(86 ±8)mm Hg比(90±9)mmHg,(118±9)mmHg比(127±8)mm Hg;均P＜0.01].②治疗后BPV均有所减少,24 h SBP变异、白昼SBP和白昼DBP变异、夜间SBP变异差异有统计学意义[(11.2 ±2.3)mm Hg比(14.7±3.1)mm Hg,(15.1±8.5)mm Hg比(18.3±7.0)mm Hg,(9.2±3.2)mm Hg比(10.4 ±2.5) mm Hg; (13.7±7.7)mm Hg比(16.6±7.3)mm Hg;P＜0.05或P＜0.01].结论 厄贝沙坦氢氯噻嗪片不仅能降低血压,而且能降低BPV,改善预后.

Effect of irbesartan and hydrochlorothiazide tablets on blood pressure and blood pressure variability of pa- tients with essential hypertension

Objective To observe the effects of irbesartan and hydrochlorothiazide tablets on blood pressure and blood pressure variability（BPV） of patients with essential hypertension. Methods Sixty patients with essential hypertension were treated with irbesartan and hydrochlorothiazide tablets 150 mg/d, the changes of 24 hours average blood pressure and BPV were compared prior to and after 8 weeks of treatment. Results The 24 hSBP, dSBP, dDBP, nSBP reduced obviously after treatment [ （ 122 ± 8 ） mm Hg （ 1 mm Hg = 0.133 kPa） vs （ 151 ± 24） mm Hg, （ 127 ± 18）ram Hg vs （156 ±19）mm Hg, （86 ±8）mm Hg vs （90±9）mm Hg, （118 ±9）mm Hg vs （127 ±8）mm Hg; all P 〈0.01 ]. There was statistically significant difference in 24 hSBPSD, dSBPSD, dDBPSD, nSBPSD between pre and post treatment[ （11.2±2.3）mm Hg vs （14.7 ±3.1）mm Hg, （15.1±8.5）mm Hg vs （18.3 ±7.0）mm Hg, （9.2±3.2）mmHgvs （10.4±2.5）mm Hg; （13.7±7.7）mm Hgvs （16.6±7.3）mmHg; P〈0.05 or P 〈0.01 ]. Conclusion Irbesartan and hydroeh-lorothiazide tablets can not only reduce hypertension, but also eomtrol BPV and improve prognosis.